<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>Program Number: 1018 Poster Board Number: B0323Presentation Time: 1:00 PM - 2:45 PMIsolation and characterization of p75NTR positive and highproliferativecorneal endothelial cells from the human cornealendotheliumSusumu Hara, Ryuhei Hayashi, Tomofumi Kageyama, MotokazuTsujikawa, Kohji Nishida. Ophthalmology, Osaka UniversityGraduate Scool of Medicine, Suita, Japan.Purpose: The corneal endothelium is believed to be developmentallyoriginated from periocular mesenchyme via neural crest. The humancorneal endothelial progenitor cells (HCEPs) have been investigatedbecause of their potential availability for the tissue regenerativemedicine. However, the existence and the properties of HCEPs havenot been elucidated yet. We attempted to isolate the HCEPs from thehuman corneal endothelium by using the specified culture system andp75 neurotrophin receptor (p75NTR).Methods: The Descemet's membranes were stripped from the humancornea, then, treated with a cell dissociated reagent. To isolate theHCEPs, the endothelial cells were seeded on the dish coated withlaminin and cultured in the serum-free media containing basicfibroblast growth factor. Expression of neural crest markers in theisolated HCEPs was examined by real-time PCR andimmunostaining.Results: The proliferating cells were appeared at around 14 daysafter the seeding, exhibited a bipolar, spindle-shaped morphology,similar to neural crest cells. Interestingly, the proliferating cellsexpressed neural crest markers, p75NTR and Sox9. The colonyforming efficiency was approximately 0.31±0.04%, showed nosignificant relation to donor ages. The proliferating cells were able toundergo passage several times in younger donors below 60 years old,and the proliferative capability was higher than that of human cornealendothelial cells cultivated by the conventional method with fetalbovine serum containing media.Conclusions: We succeeded in the isolation of HCEPs which hadhigh p75NTR expression and proliferative capability.Commercial Relationships: Susumu Hara, None; RyuheiHayashi, None; Tomofumi Kageyama, None; MotokazuTsujikawa, Shionogi & Co. (C), Daiichi Sankyo Co. (F), DaiichiSankyo Co. (R), Santen Co. (R), AMO Co. (R); Kohji Nishida,Alcon (C), Alcon (F), HOYA (F), Senju (F), Pfizer (F), Santen (F),Osaka University (P)Support: Grants-in-Aid for Scientific Research from the Ministry ofHealth, Labor and Welfare and from National Institute of BiomedicalInnovation in JapanProgram Number: 1019 Poster Board Number: B0324Presentation Time: 1:00 PM - 2:45 PMSpatial transcriptome of human cornea using next generationsequencerSuguru Nakagawa 1 , Tomohiko Usui 1 , Hiroki Ueda 2 , Genta Nagae 2 ,Shogo Yamamoto 2 , Satoru Yamagami 1 , Hiroyuki Aburatani 2 , ShiroAmano 1 . 1 Ophthalmology, Univ of Tokyo Sch of Med, Tokyo, Japan;2 Div of Genome Science, RCAST, University of Tokyo, RCAST,University of Tokyo, Tokyo, Japan.Purpose: <strong>Cornea</strong> consists of anatomically distinct three layers,corneal epithelium (CEp), corneal stroma (CS), corneal endothelium(CEn), that have different developmental lineages and molecularfunctions. To reveal their transcriptional program, we performedspatial gene expression analysis of human cornea using nextgeneration sequencer.Methods: 100 ng of total RNA was extracted from themacroscopically dissected tissue fractions; CEp, CS, CEn, limbalepithelium (LEp) and conjunctiva (Cj) of the human donorcorneoscleral tissue. For each sample, approximately 150 million of100-bp, paired-end reads were sequenced (HiSeq2000, Illumina) andmapped against transcriptome database using BWA aligner. Quantityof 86,817 transcripts was corrected by gene/exon length(RPKM/FPKM), and then compared using regression analysis.Results: 24,601 Transcript (28.3%) were expressed in common withall cell fractions. Global comparison of each spatial transcriptomeshowed that CS shows the closest pattern against CEn (correlationcoefficient (R^2); CEn vs. CS 0.844, vs. CEp 0.807, vs. LEp 0.811,vs. Cj 0.821). We identified the candidate transcripts significantlyupregulated in CEn against other tissue fractions; CEp (n=1,760),LEp (n=1,513), CS (n=1,482), Cj (n=1,322), respectively. Ascommonly up-regulated transcripts in the CEn, we listed up morethan 300 coding genes in addition to previously reported CEnspecificmarkers such as COL8A2, CA2, SLC4A4, CDH2.Conclusions: We successfully demonstrated the layer-specificpattern of transcriptome and identified the novel up-regulated genesin CEn. This resource information is useful for understanding thespatial difference in transcriptional program to modulate celllineages.Commercial Relationships: Suguru Nakagawa, None; TomohikoUsui, None; Hiroki Ueda, None; Genta Nagae, None; ShogoYamamoto, None; Satoru Yamagami, None; Hiroyuki Aburatani,None; Shiro Amano, Topcon (P)Program Number: 1020 Poster Board Number: B0325Presentation Time: 1:00 PM - 2:45 PMHuman cornea proteome: Identification and quantitation of theproteins of the three main layers including epithelium, stromaand endotheliumThomas Dyrlund 1 , Ebbe Toftgaard Poulsen 1 , Carsten Scavenius 1 ,Camilla Lund Nikolajsen 1 , Ida B. Thøgersen 1 , Henrik Vorum 2 , Jan J.Enghild 1 . 1 Department of Molecular Biology, University of Aarhus,Aarhus C., Denmark; 2 Department of Ophthalmology, AalborgHospital, Aarhus University Hospital, Aalborg, Denmark.Purpose: Diseases of the cornea are common and refer to conditionslike infections, injuries and genetic defects. Morphologically, manycorneal diseases affect only certain layers of the cornea and separateanalysis of the individual layers is therefore of interest to explore thebasic molecular mechanisms involved in corneal health and disease.Methods: The three main layers including the epithelium, stroma andendothelium of healthy human corneas were isolated and the proteinswere (i) separated by SDS-PAGE followed by in-gel trypsinization,(ii) in-solution digested without prior protein separation or, (iii) insolutiondigested followed by cation exchange chromatography. Theresulting peptides were separated by LC-MS/MS and analysed on aTripleTOF 5600 mass spectrometer. Proteins were identified in theSwiss-Prot database using the Mascot algorithm and quantified usingMascot Distiller. Data extraction and processing was done using MSData Miner.Results: A total of 3250 unique Swiss-Prot annotated proteins wereidentified in human corneas, 2737 in the epithelium, 1679 in thestroma and 880 in the endothelial layer. Of these, 1787 proteins havenot previously been identified in the human cornea by massspectrometry. In total, 771 proteins were quantified, 157 based on insolutiondigestion and 770 based on SDS-PAGE separation followedby in-gel digestion of excised gel pieces. Protein analysis revealedthat many of the identified proteins were human plasma proteinsinvolved in the complement system, coagulation and defence againstpathogen infections.Conclusions: The separation of human corneas into the three mainlayers combined with modern mass spectrometry provides new©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>insight into the proteins present in the individual layers and therelative abundance in each layer. This provides a useful referencedataset when exploring basic molecular mechanisms involved incorneal diseases, many of which are restricted to a specific corneallayer.Commercial Relationships: Thomas Dyrlund, None; EbbeToftgaard Poulsen, None; Carsten Scavenius, None; CamillaLund Nikolajsen, None; Ida B. Thøgersen, None; Henrik Vorum,None; Jan J. Enghild, NoneSupport: R01 EY012712Program Number: 1021 Poster Board Number: B0326Presentation Time: 1:00 PM - 2:45 PMImmunocytochemical analysis after treatment withosmoprotective and oil containing lubricants in dry eye andrefractive surgery patientsRenata R. Loureiro, Rossen M. Hazarbassanov, Joyce L. Covre,Priscila C. Cristovam, Jeison D. Barros, Jose A. Gomes.Ophthalmology, UNIFESP, Sao Paulo, Brazil.Purpose: To evaluate immunostaining patterns of inflammation andosmoprotection markers after treatment with osmoprotectivelubricant compared to oil containing and non-osmoprotectivelubricants, in evaporative dysfunctional tear syndrome (EDTS) postrefractive surgery patients.Methods: 45 patients (74,28 % female)(Mean age ± SD, 32.5±10.35) were enrolled. Participants were randomized to receivetopical drops QID for the 1st month and BID for the following 2months of Optive®, FreshTears®, (Allergan, Inc., Irvine,California).They were divided into 2 groups, (A) 15 patients withEDTS, (B) 30 patients without EDTS who were referred to eitherLASIK (15) or PRK (15). In group A, 5 patients (10 eyes) weretreated with either Optive®, FreshTears® or Endura®, as well as 5patients (10 eyes) from group B/PRK and 5 patients (10 eyes) fromgroup B/LASIK. All patients were submitted to the following testsfor EDTS diagnose: Ocular Surface Disease Index (OSDI), patientsymptomatology questionnaire, visual acuity (VA), biomicroscopy,Schirmer I test without anesthesia, tear film osmolarity, fluoresceinbreak up time (FBUT), fluorescein and lissamine green 1% staining(Oxford grading), impression cytology (IC) andimmunocytochemistry (ICC) for an inflammation marker (HLA-DR)and L-carnitine, osmoprotective component.Results: Pre-treatment and 3 month follow-up exams are completedfor both groups. ICC of conjunctiva samples showed 42.86%positivity for HLA-DR staining, on group A and 20% for groupB/LASIK, 30% for PRK, before treatment (p=0.4896, χ2 test). Therewas lower HLA-DR staining for EDTS patients treated with Optive®and Endura® (28.11% and 35.6%). ICC for L-carnitine staining was53.33% positive for A, 22% for LASIK and10% for PRK subgroup,before treatment (p=0.041, χ2 test). L-carnitine ICC staining posttreatmentshowed high positivity for FreshTears® and Endura®groups, in contrast to a lower staining for Optive® subgroup.Conclusions: Conjunctival cells showed tendency of higherexpression of inflammation marker HLA-DR on EDTS patients, andfor L-carnitine as well, which could be reduced after osmoprotectivetherapy. Those markers could be used to detect EDTS in early stageand as prognostic tool for EDTS treatment.Commercial Relationships: Renata R. Loureiro, None; Rossen M.Hazarbassanov, None; Joyce L. Covre, None; Priscila C.Cristovam, None; Jeison D. Barros, None; Jose A. Gomes,Allergan (C), Pfizer (C), Genon (C), MSD (C)Support: None in the Support field belowClinical Trial: nct01741987Program Number: 1022 Poster Board Number: B0327Presentation Time: 1:00 PM - 2:45 PMThe Regeneration Potential of Mouse Lacrimal Gland FollowingDuct Ligation ProcedureYing Liu 1 , Tetsuya Kawakita 1 , Machiko Sugiyama 1 , MasatoshiHirayama 1 , Motoko Kawashima 1 , Yoko Ogawa 1 , Masataka Ito 2 ,Shigeto Shimmura 1 , Kazuo Tsubota 1 . 1 Ophthalmology, KeioUniversity School of Medicine, Tokyo, Japan; 2 National DefenseMedicine College, Saitama, Japan.Purpose: To observe the regeneration and proliferation potential ofadult mouse lacrimal gland (LG) following duct-ligation (DL)procedure and duct-ligation-release (DLR) procedure.Methods: Adult mice were divided into two groups. One group wassubjected to the DL of the right LG, and glands were collected at day0, 3, 7 and 14 after DL (n=3-5, at each time point). Another groupwas subjected to the DLR for 7 days and the ligation was released atday 7 of the right LG. Then the glands were collected at day 9, 12, 14and 17 after the ligation was released. Tear production and the glandweight were measured during the duct ligation / release (DL/R)procedure. Tissues were investigated by Hematein & Eosin (H&E)staining and immunohistochemistry.Results: Tear secretion of DL and DLR group at day 3, 7, 9, 12 and14, has significantly decreased compared with control (p
- Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
- Page 4 and 5:
ARVO 2013 Annual Meeting Abstracts
- Page 6 and 7:
ARVO 2013 Annual Meeting Abstracts
- Page 8 and 9:
ARVO 2013 Annual Meeting Abstracts
- Page 10:
ARVO 2013 Annual Meeting Abstracts
- Page 13 and 14:
ARVO 2013 Annual Meeting Abstracts
- Page 16 and 17:
ARVO 2013 Annual Meeting Abstracts
- Page 18 and 19:
ARVO 2013 Annual Meeting Abstracts
- Page 20 and 21:
ARVO 2013 Annual Meeting Abstracts
- Page 22 and 23:
ARVO 2013 Annual Meeting Abstracts
- Page 24 and 25:
ARVO 2013 Annual Meeting Abstracts
- Page 26 and 27:
ARVO 2013 Annual Meeting Abstracts
- Page 28 and 29:
ARVO 2013 Annual Meeting Abstracts
- Page 30 and 31:
ARVO 2013 Annual Meeting Abstracts
- Page 32 and 33:
ARVO 2013 Annual Meeting Abstracts
- Page 34 and 35: ARVO 2013 Annual Meeting Abstracts
- Page 36 and 37: ARVO 2013 Annual Meeting Abstracts
- Page 38 and 39: ARVO 2013 Annual Meeting Abstracts
- Page 40 and 41: ARVO 2013 Annual Meeting Abstracts
- Page 42 and 43: ARVO 2013 Annual Meeting Abstracts
- Page 44 and 45: ARVO 2013 Annual Meeting Abstracts
- Page 46 and 47: ARVO 2013 Annual Meeting Abstracts
- Page 48 and 49: ARVO 2013 Annual Meeting Abstracts
- Page 50 and 51: ARVO 2013 Annual Meeting Abstracts
- Page 52 and 53: ARVO 2013 Annual Meeting Abstracts
- Page 54 and 55: ARVO 2013 Annual Meeting Abstracts
- Page 56 and 57: ARVO 2013 Annual Meeting Abstracts
- Page 58 and 59: ARVO 2013 Annual Meeting Abstracts
- Page 60 and 61: ARVO 2013 Annual Meeting Abstracts
- Page 62 and 63: ARVO 2013 Annual Meeting Abstracts
- Page 64 and 65: ARVO 2013 Annual Meeting Abstracts
- Page 66 and 67: ARVO 2013 Annual Meeting Abstracts
- Page 68 and 69: ARVO 2013 Annual Meeting Abstracts
- Page 70 and 71: ARVO 2013 Annual Meeting Abstracts
- Page 72 and 73: ARVO 2013 Annual Meeting Abstracts
- Page 74 and 75: ARVO 2013 Annual Meeting Abstracts
- Page 76 and 77: ARVO 2013 Annual Meeting Abstracts
- Page 78 and 79: ARVO 2013 Annual Meeting Abstracts
- Page 80 and 81: ARVO 2013 Annual Meeting Abstracts
- Page 82 and 83: ARVO 2013 Annual Meeting Abstracts
- Page 86 and 87: ARVO 2013 Annual Meeting Abstracts
- Page 88 and 89: ARVO 2013 Annual Meeting Abstracts
- Page 90 and 91: ARVO 2013 Annual Meeting Abstracts
- Page 92 and 93: ARVO 2013 Annual Meeting Abstracts
- Page 94 and 95: ARVO 2013 Annual Meeting Abstracts
- Page 96 and 97: ARVO 2013 Annual Meeting Abstracts
- Page 98 and 99: ARVO 2013 Annual Meeting Abstracts
- Page 100 and 101: ARVO 2013 Annual Meeting Abstracts
- Page 102 and 103: ARVO 2013 Annual Meeting Abstracts
- Page 104 and 105: ARVO 2013 Annual Meeting Abstracts
- Page 106 and 107: ARVO 2013 Annual Meeting Abstracts
- Page 108 and 109: ARVO 2013 Annual Meeting Abstracts
- Page 110 and 111: ARVO 2013 Annual Meeting Abstracts
- Page 112 and 113: ARVO 2013 Annual Meeting Abstracts
- Page 114 and 115: ARVO 2013 Annual Meeting Abstracts
- Page 116 and 117: ARVO 2013 Annual Meeting Abstracts
- Page 118 and 119: ARVO 2013 Annual Meeting Abstracts
- Page 120 and 121: ARVO 2013 Annual Meeting Abstracts
- Page 122 and 123: ARVO 2013 Annual Meeting Abstracts
- Page 124 and 125: ARVO 2013 Annual Meeting Abstracts
- Page 126 and 127: ARVO 2013 Annual Meeting Abstracts
- Page 128 and 129: ARVO 2013 Annual Meeting Abstracts
- Page 130 and 131: ARVO 2013 Annual Meeting Abstracts
- Page 132 and 133: ARVO 2013 Annual Meeting Abstracts
- Page 134 and 135:
ARVO 2013 Annual Meeting Abstracts
- Page 136 and 137:
ARVO 2013 Annual Meeting Abstracts
- Page 138 and 139:
ARVO 2013 Annual Meeting Abstracts
- Page 140 and 141:
ARVO 2013 Annual Meeting Abstracts
- Page 142 and 143:
ARVO 2013 Annual Meeting Abstracts
- Page 144 and 145:
ARVO 2013 Annual Meeting Abstracts
- Page 146 and 147:
ARVO 2013 Annual Meeting Abstracts
- Page 148 and 149:
ARVO 2013 Annual Meeting Abstracts
- Page 150 and 151:
ARVO 2013 Annual Meeting Abstracts
- Page 152 and 153:
ARVO 2013 Annual Meeting Abstracts
- Page 154 and 155:
ARVO 2013 Annual Meeting Abstracts
- Page 156 and 157:
ARVO 2013 Annual Meeting Abstracts
- Page 158 and 159:
ARVO 2013 Annual Meeting Abstracts
- Page 160 and 161:
ARVO 2013 Annual Meeting Abstracts
- Page 162 and 163:
ARVO 2013 Annual Meeting Abstracts
- Page 164 and 165:
ARVO 2013 Annual Meeting Abstracts
- Page 166 and 167:
ARVO 2013 Annual Meeting Abstracts
- Page 168 and 169:
ARVO 2013 Annual Meeting Abstracts
- Page 170 and 171:
ARVO 2013 Annual Meeting Abstracts
- Page 172 and 173:
ARVO 2013 Annual Meeting Abstracts
- Page 174 and 175:
ARVO 2013 Annual Meeting Abstracts
- Page 176 and 177:
ARVO 2013 Annual Meeting Abstracts
- Page 178 and 179:
ARVO 2013 Annual Meeting Abstracts
- Page 180 and 181:
ARVO 2013 Annual Meeting Abstracts
- Page 182 and 183:
ARVO 2013 Annual Meeting Abstracts
- Page 184 and 185:
ARVO 2013 Annual Meeting Abstracts
- Page 186 and 187:
ARVO 2013 Annual Meeting Abstracts
- Page 188 and 189:
ARVO 2013 Annual Meeting Abstracts
- Page 190 and 191:
ARVO 2013 Annual Meeting Abstracts
- Page 192 and 193:
ARVO 2013 Annual Meeting Abstracts
- Page 194 and 195:
ARVO 2013 Annual Meeting Abstracts
- Page 196 and 197:
ARVO 2013 Annual Meeting Abstracts
- Page 198 and 199:
ARVO 2013 Annual Meeting Abstracts
- Page 200 and 201:
ARVO 2013 Annual Meeting Abstracts
- Page 202 and 203:
ARVO 2013 Annual Meeting Abstracts
- Page 204 and 205:
ARVO 2013 Annual Meeting Abstracts
- Page 206 and 207:
ARVO 2013 Annual Meeting Abstracts
- Page 208 and 209:
ARVO 2013 Annual Meeting Abstracts
- Page 210 and 211:
ARVO 2013 Annual Meeting Abstracts
- Page 212 and 213:
ARVO 2013 Annual Meeting Abstracts
- Page 214 and 215:
ARVO 2013 Annual Meeting Abstracts
- Page 216 and 217:
ARVO 2013 Annual Meeting Abstracts
- Page 218 and 219:
ARVO 2013 Annual Meeting Abstracts
- Page 220 and 221:
ARVO 2013 Annual Meeting Abstracts
- Page 222 and 223:
ARVO 2013 Annual Meeting Abstracts
- Page 224 and 225:
ARVO 2013 Annual Meeting Abstracts
- Page 226 and 227:
ARVO 2013 Annual Meeting Abstracts
- Page 228 and 229:
ARVO 2013 Annual Meeting Abstracts
- Page 230 and 231:
ARVO 2013 Annual Meeting Abstracts
- Page 232 and 233:
ARVO 2013 Annual Meeting Abstracts
- Page 234 and 235:
ARVO 2013 Annual Meeting Abstracts
- Page 236 and 237:
ARVO 2013 Annual Meeting Abstracts
- Page 238 and 239:
ARVO 2013 Annual Meeting Abstracts
- Page 240 and 241:
ARVO 2013 Annual Meeting Abstracts
- Page 242 and 243:
ARVO 2013 Annual Meeting Abstracts
- Page 244 and 245:
ARVO 2013 Annual Meeting Abstracts
- Page 246 and 247:
ARVO 2013 Annual Meeting Abstracts
- Page 248 and 249:
ARVO 2013 Annual Meeting Abstracts
- Page 250 and 251:
ARVO 2013 Annual Meeting Abstracts
- Page 252 and 253:
ARVO 2013 Annual Meeting Abstracts
- Page 254 and 255:
ARVO 2013 Annual Meeting Abstracts
- Page 256 and 257:
ARVO 2013 Annual Meeting Abstracts
- Page 258 and 259:
ARVO 2013 Annual Meeting Abstracts
- Page 260 and 261:
ARVO 2013 Annual Meeting Abstracts
- Page 262 and 263:
ARVO 2013 Annual Meeting Abstracts
- Page 264 and 265:
ARVO 2013 Annual Meeting Abstracts
- Page 266 and 267:
ARVO 2013 Annual Meeting Abstracts
- Page 268 and 269:
ARVO 2013 Annual Meeting Abstracts
- Page 270 and 271:
ARVO 2013 Annual Meeting Abstracts
- Page 272 and 273:
ARVO 2013 Annual Meeting Abstracts
- Page 274 and 275:
ARVO 2013 Annual Meeting Abstracts
- Page 276 and 277:
ARVO 2013 Annual Meeting Abstracts
- Page 278 and 279:
ARVO 2013 Annual Meeting Abstracts
- Page 280 and 281:
ARVO 2013 Annual Meeting Abstracts
- Page 282 and 283:
ARVO 2013 Annual Meeting Abstracts
- Page 284 and 285:
ARVO 2013 Annual Meeting Abstracts
- Page 286 and 287:
ARVO 2013 Annual Meeting Abstracts
- Page 288 and 289:
ARVO 2013 Annual Meeting Abstracts
- Page 290 and 291:
ARVO 2013 Annual Meeting Abstracts
- Page 292 and 293:
ARVO 2013 Annual Meeting Abstracts
- Page 294 and 295:
ARVO 2013 Annual Meeting Abstracts
- Page 296 and 297:
ARVO 2013 Annual Meeting Abstracts
- Page 298 and 299:
ARVO 2013 Annual Meeting Abstracts
- Page 300 and 301:
ARVO 2013 Annual Meeting Abstracts
- Page 302 and 303:
ARVO 2013 Annual Meeting Abstracts
- Page 304 and 305:
ARVO 2013 Annual Meeting Abstracts
- Page 306 and 307:
ARVO 2013 Annual Meeting Abstracts
- Page 308 and 309:
ARVO 2013 Annual Meeting Abstracts
- Page 310 and 311:
ARVO 2013 Annual Meeting Abstracts
- Page 312 and 313:
ARVO 2013 Annual Meeting Abstracts
- Page 314 and 315:
ARVO 2013 Annual Meeting Abstracts
- Page 316 and 317:
ARVO 2013 Annual Meeting Abstracts
- Page 318 and 319:
ARVO 2013 Annual Meeting Abstracts
- Page 320 and 321:
ARVO 2013 Annual Meeting Abstracts
- Page 322 and 323:
ARVO 2013 Annual Meeting Abstracts
- Page 324 and 325:
ARVO 2013 Annual Meeting Abstracts
- Page 326 and 327:
ARVO 2013 Annual Meeting Abstracts
- Page 328 and 329:
ARVO 2013 Annual Meeting Abstracts
- Page 330 and 331:
ARVO 2013 Annual Meeting Abstracts
- Page 332 and 333:
ARVO 2013 Annual Meeting Abstracts
- Page 334 and 335:
ARVO 2013 Annual Meeting Abstracts
- Page 336 and 337:
ARVO 2013 Annual Meeting Abstracts
- Page 338 and 339:
ARVO 2013 Annual Meeting Abstracts
- Page 340 and 341:
ARVO 2013 Annual Meeting Abstracts
- Page 342 and 343:
ARVO 2013 Annual Meeting Abstracts
- Page 344 and 345:
ARVO 2013 Annual Meeting Abstracts
- Page 346 and 347:
ARVO 2013 Annual Meeting Abstracts
- Page 348 and 349:
ARVO 2013 Annual Meeting Abstracts
- Page 350 and 351:
ARVO 2013 Annual Meeting Abstracts
- Page 352 and 353:
ARVO 2013 Annual Meeting Abstracts
- Page 354 and 355:
ARVO 2013 Annual Meeting Abstracts
- Page 356 and 357:
ARVO 2013 Annual Meeting Abstracts
- Page 358 and 359:
ARVO 2013 Annual Meeting Abstracts
- Page 360 and 361:
ARVO 2013 Annual Meeting Abstracts
- Page 362 and 363:
ARVO 2013 Annual Meeting Abstracts
- Page 364 and 365:
ARVO 2013 Annual Meeting Abstracts
- Page 366 and 367:
ARVO 2013 Annual Meeting Abstracts
- Page 368 and 369:
ARVO 2013 Annual Meeting Abstracts
- Page 370 and 371:
ARVO 2013 Annual Meeting Abstracts
- Page 372 and 373:
ARVO 2013 Annual Meeting Abstracts
- Page 374 and 375:
ARVO 2013 Annual Meeting Abstracts
- Page 376 and 377:
ARVO 2013 Annual Meeting Abstracts
- Page 378 and 379:
ARVO 2013 Annual Meeting Abstracts
- Page 380 and 381:
ARVO 2013 Annual Meeting Abstracts
- Page 382 and 383:
ARVO 2013 Annual Meeting Abstracts